Prelude Therapeutics Inc (PRLD)

• $1.21

  $1.29

  $1.22
  

  0.82%

  Downside

  Day's Volatility :6.03%

  Upside

  5.25%

  
• $1.10

  $6.80

  $1.22
  

  9.84%

  Downside

  52 Weeks Volatility :83.82%

  Upside

  82.06%

  

Returns

What analysts predicted

Upside of 342.62%

• Orbimed Advisors, LLC

  19.83%

• Baker Bros Advisors LP

  18.40%

• Deerfield Management Co

  7.51%

• Boxer Capital LLC

  4.67%

• BlackRock Inc

  1.94%

• Vanguard Group Inc

  1.84%

prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.